EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Investigating Hybrid PLGA-Lipid Nanoparticles as an Innovative Delivery Tool for Palmitoylethanolamide to Muscle Cells

Eleonora Maretti iD, Susanna Molinari iD, Sonia Partel, Beatrice Recchia iD, Cecilia Rustichelli iD, Eliana Leo iD

Pharmaceutics · 30.10.2025 · 17 (11) · 1412

DOI: 10.3390/pharmaceutics17111412 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 30.10.2025. Verfasst von Eleonora Maretti und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Life Sciences, University of Modena and Reggio Emilia, Via Campi 103, 41125 Modena, Italy. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union Next Generation EU.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Palmitoylethanolamide (PEA) is an endogenous lipid mediator with endocannabinoid-like activity. Despite its therapeutic potential in muscle-related inflammatory disorders, including sarcopenia, its clinical use is limited by poor solubility and bioavailability. To overcome these issues, we developed hybrid nanoparticles combining poly(lactic-co-glycolic acid) (PLGA) and lipids to enhance PEA encapsulation and ok delivery.

Methods

PEA-loaded hybrid nanoparticles (PEA-Hyb-np) were produced via a modified single-emulsion solvent evaporation method using stearic acid and Gelucire® 50/13 as lipid components. Characterization included particle size, morphology, PDI, and zeta potential, as well as DSC, FT-IR, and XRD analyses. For the biological evaluation in a C2C12 myoblasts cell culture, coumarin-6-labeled nanoparticles were employed.

Results

PEA-Hyb-np showed mean particle sizes of ~150 nm, with internal lipid–polymer phase separation. This structure enabled high encapsulation efficiency (79%) and drug loading (44.2 mg/g). Drug release in physiological and non-physiological media was enhanced due to drug amorphization, confirmed by DSC, FT-IR, and XRD analyses. Cytocompatibility studies showed no toxicity and improved cell viability compared to unloaded nanoparticles. Cellular uptake studies by confocal microscopy and flow cytometry demonstrated efficient and time-dependent internalization.

Conclusions

PEA-Hyb-np represent a promising delivery platform to improve the solubility, bioavailability, and therapeutic efficacy of PEA for muscle-targeted applications.

Schlagwörter

Stichwörter der Autor:innen

PEAgeluciremuscle cellsmyoblastnanocarrierssarcopeniastearic acid

Autor:innen und Institutionen

  • Department of Life Sciences, University of Modena and Reggio Emilia, Via Campi 103, 41125 Modena, Italy.
  • Department of Life Sciences, University of Modena and Reggio Emilia, Via Campi 287, 41125 Modena, Italy.

ORCID-Profile: Eleonora Maretti, Susanna Molinari, Beatrice Recchia, Cecilia Rustichelli, Eliana Leo

Förderung

  • European Union Next Generation EU

Zitieren

APA

Maretti, E., Molinari, S., Partel, S., Recchia, B., Rustichelli, C., & Leo, E. (2025). Investigating Hybrid PLGA-Lipid Nanoparticles as an Innovative Delivery Tool for Palmitoylethanolamide to Muscle Cells. Pharmaceutics, 17(11), 1412. https://doi.org/10.3390/pharmaceutics17111412

Vancouver

Maretti E, Molinari S, Partel S, Recchia B, Rustichelli C, Leo E. Investigating Hybrid PLGA-Lipid Nanoparticles as an Innovative Delivery Tool for Palmitoylethanolamide to Muscle Cells. Pharmaceutics. 2025;17(11):1412. doi:10.3390/pharmaceutics17111412

BibTeX
@article{Maretti2025,
  author = {Maretti, Eleonora and Molinari, Susanna and Partel, Sonia and Recchia, Beatrice and Rustichelli, Cecilia and Leo, Eliana},
  title = {Investigating Hybrid PLGA-Lipid Nanoparticles as an Innovative Delivery Tool for Palmitoylethanolamide to Muscle Cells},
  journal = {Pharmaceutics},
  year = {2025},
  volume = {17},
  number = {11},
  pages = {1412},
  doi = {10.3390/pharmaceutics17111412}
}
Kostenlos starten →